0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Resihance 40mg

Resihance 40mg (Regorafenib)

Resihance is an anticancer drug which is;

Indicated for the treatmentof Hepatocellular carcinoma

Indicated for the treatment of Colorectal cancer

Indicated for the treatment of Gastrointestinal stromal tumor

Feature
Brand name:
Resihance
Active substance:
Regorafenib 40mg
Manufacturer:
Bayer
Packaging:
28 Tablets
Product form:
Tablet
In stock
Active substance: Regorafenib
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Resihance consist of protein kinase inhibitor with a similar structure to sorafenib. It is hoping to act by prohibiting multiple signalling pathways contains in angiogenesis and tumour growth.
Resihance is commonly given after other chemotherapy have been tried without success.
Resihance which is used asprescription drugs under the supervision of medical practioners.

INDICATION

Resihance is an anticancer drug which is;

Indicated for the treatmentof Hepatocellular carcinoma

Indicated for the treatment of Colorectal cancer

Indicated for the treatment of Gastrointestinal stromal tumor

MECHANISM OF ACTION

Regorafenib consist of systemic therapy which works throughout your body to promote fight certain cancers. Regorafenib belongs to a multikinase inhibitor, may work by stopping some proteins on certain normal and cancer cells. In this way, Regorafenib may inhibit cancers from growing and spreading for a period.

Cancer contains the uncontrolled growth of certain cells in the body.

Regorafenib may interfere with the signals whichinform cancer cells to replicate and may slow the cancer from spreading to other parts of the body.

Regorafenib may also block the creation of new blood vessels that feed cancer cells.

PHARMACOKINETICS

 Time to peak plasma is 4 hours and concentration is 2.5mcg/mL for single dose;
Bioavailability is 69-83%
Regorafenib has protein bounding about 99.5% and M-2 active metabolite is 99.8%; M-5 active metabolite is 99.95%
The drug Regorafenib is metabolized by CYP3A4 and UGT1A9
Eliminated via feces 71%; 19% urine (within 12 days of single dose)
Half-life of
Regorafenib is 28 hr
M-2 active metabolite is 25 hr
M-5 active metabolite is 51hr.

DOSAGE MANAGEMENT

Hepatocellular carcinoma :
The usual dose for Hepatocellular carcinoma is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Follow the treatment of this conditions until disease progression or undesirable toxicity
Colorectal cancer :
The usual dose for Colorectal cancer is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Gastrointestinal stromal tumor :
The usual dose for Gastrointestinal stromal tumor is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.

PRECAUTION

• Have high risk for HFSR/PPES and rash; a more incidence of HFSR resulted in Asian patients; stop and then reduce or stop regorafenib depending on severity and persistence of dermatologic toxicity.
• While on treatment with Resihance will occur Myocardial ischemia and infarction seen in clinical trials; withhold Nublexa for new or acute cardiac ischemia/infarction and restart only after resolution of acute ischemic events.
• When administrating Nublexa 40mg, one case report of reversible posterior leukoencephalopathy syndrome (RPLS) occurred (1 of 1100 treated patients); discontinue therapy if RPLS occurs.
• Using Resihance treatment will have Serious drug-induced liver injury with fatal outcome appeared in Nublexa-treated patients in clinical trials. Some of the cases, liver dysfunction occurred within the first 2 months of treatment and was characterized by a hepatocellular pattern of injury.
• When administrating Resihance will have heavy risk for haemorrhage; stop therapy for severe or life-threatening haemorrhage
• When administrating Resihance will have high risk of infections resulted; most common infections includes urinary tract infections, nasopharyngitis, mucocutaneous and systemic fungal infections and pneumonia

SIDE EFFECTS

Common side effects of Resihance :
Diarrhea, Low platelets, Mouth ulcers, Weight loss, High bilirubin in the blood, Hand-foot syndrome , Infection, Anemia, Increased liver enzymes (AST, ALT), Fatigue, High blood pressure, Protein in the urine, Reduced Calcium, Low phosphorous, Low white blood cells, Decreased appetite, Increased lipase & amylase, Voice disorder (Dysphonia), Low sodium, Nausea.
Less common side effects of Resihance :
Increased bleeding, Headache, Alopecia, Pain, Fever, Rash, Low potassium, Decreased blood clotting.

DRUG INTERACTION

Co administration of Resihance with strong CYP3A4 inducers will decrease Regorafenib plasma concentrations and increased plasma concentration of active metabolite M-2; M-5.

Co administration of Resihance with strong CYP3A4 inhibitor will increase Regorafenib plasma concentration and decreased plasma concentration of active metabolite M-2; M-5.

Co administration of Resihance with BCRP substrate will increased the plasma concentration of the BCRP substrate.

PREGNANCY

Pregnancy category D: The drug has no data available on use in pregnant women. Inform pregnant women about the probable hazard to a foetus.

LACTATION

Excretion into human milk is unknown.
Do not breast feed during the treatment with Resihence.

STORAGE

Store the Resihance at 25°C (77°C).
Keep the drug in its original container bottle.

MISSED DOSE

If dose is failed to take, Patients must consult with medical practitioner and follow the instructions given by them.

Hence missed dose must be avoid and follow the regular dosing schedule.

Feature
Brand name
Resihance
Active substance
Regorafenib 40mg
Manufacturer
Bayer
Packaging
28 Tablets
Product form
Tablet
Strength
40mg
Resihance 40mg отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
Lorem Ipsum adalah text contoh digunakan didalam industri pencetakan dan typesetting. Lorem Ipsum telah menjadi text contoh semenjak tahun ke 1500an, apabila pencetak yang kurang terkenal mengambil sebuah galeri cetak dan merobakanya menjadi satu buku spe